Record overview
Status and phase
Status: COMPLETED
Phase: PHASE1, PHASE2
Sponsor: Genelux Corporation
Condition: Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
NCT02759588
Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.